Rex Pei

Rex Pei has worked in the biotechnology industry since 2004. Rex began their career as a graduate student at the University of Michigan. In 2010, they joined Amgen as a Scientist. In 2014, they joined Astellas Pharma US as a Senior Scientist, where they worked for Agensys, a subsidiary of Astellas. Rex led the In-process analytical group to support Agensys mAb and ADC process development, and provided analytical support and strategy for cell culture, purification and conjugation process development and in-process testing. Rex also developed high-throughput analytical assays to accommodate high sample testing demand from multiple pipeline projects. In 2016, they joined Ambrx as a Senior Scientist, Analytical and Formulation Development. In 2018, they joined MabPlex International Co., Ltd. as an Associate Director, Analytical and Formulation Development. In 2019, they joined Maverick Therapeutics as an Associate Director. In 2021, they joined Takeda as an Associate Director of Analytical and Formulation Development & Quality Control. Currently, they are the Senior Director of Analytical Development and Quality Control at Werewolf Therapeutics, a position they have held since 2022.

Rex Pei received their Doctor of Philosophy (PhD) in analytical chemistry from the University of Michigan in 2009. Prior to that, they obtained their B.S in Chemistry from Peking University in 2003.